Neuroscience
Today's recommended article to read; abstract from PubMed:
Bergmans BA & De Strooper B. gamma-secretases: From cell biology to therapeutic strategies. Lancet Neurology. 2010 Feb; 9(2 ): 215-226.
Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium; Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium.
Presenilins form the catalytic part of the gamma-secretases, protein complexes that are responsible for the intramembranous cleavage of transmembrane proteins. The presenilins are involved in several biological functions, but are best known for their role in the generation of the beta-amyloid (Abeta) peptide in Alzheimer's disease and are therefore thought to be important drug targets for this disorder. Mutations in the presenilin genes cause early-onset familial Alzheimer's disease, but mutation carriers have substantial phenotypic heterogeneity. Recent evidence implicating presenilin mutations in non-Alzheimer's dementias, including frontotemporal dementia and Lewy body dementia, warrants further investigation. An increased understanding of the diversity of the molecular cell biology of the gamma-secretase complex and the effects of clinical mutations in the presenilin genes might help pave the way for improved development of drugs that are designed to target gamma-secretase enzymatic activity in Alzheimer's disease and potentially in other neurological diseases. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
PMID: 20129170 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...
- Alzheimer's: Impaired Beta-amyloid Clearance
From the NIH: Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease 09 December 2010 In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers...
- Upcoming Event:alzheimer's Drug Discovery (jersey City, Nj, 14-15 September)
The 10th international conference on Alzheimer's disease drug discovery takes place next week on the 14th and 15th in Jersey City, NJ. From the conference website: "The 10th International Conference on Alzheimer's Disease Drug Discovery is presented...
- Neuropsychology Abstract Of The Day: Sorl1 And Alzheimer Disease
Ekaterina Rogaeva, Yan Meng, Joseph H Lee, Yongjun Gu, Toshitaka Kawarai, et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics, Published online: 14 January 2007; | doi:10.1038/ng1943....
- Alzheimer Disease
From The Boston Globe: Mind mystery Alzheimer's disease appears to have multiple causes, and scientists are slowly unraveling them By Alice Dembner, Globe Staff March 29, 2005 A century after Alois Alzheimer identified the debilitating dementia that...
Neuroscience
Neuropsychology Abstract of the Day: Alzheimer Drug Development
Today's recommended article to read; abstract from PubMed:
Bergmans BA & De Strooper B. gamma-secretases: From cell biology to therapeutic strategies. Lancet Neurology. 2010 Feb; 9(2 ): 215-226.
Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium; Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium.
Presenilins form the catalytic part of the gamma-secretases, protein complexes that are responsible for the intramembranous cleavage of transmembrane proteins. The presenilins are involved in several biological functions, but are best known for their role in the generation of the beta-amyloid (Abeta) peptide in Alzheimer's disease and are therefore thought to be important drug targets for this disorder. Mutations in the presenilin genes cause early-onset familial Alzheimer's disease, but mutation carriers have substantial phenotypic heterogeneity. Recent evidence implicating presenilin mutations in non-Alzheimer's dementias, including frontotemporal dementia and Lewy body dementia, warrants further investigation. An increased understanding of the diversity of the molecular cell biology of the gamma-secretase complex and the effects of clinical mutations in the presenilin genes might help pave the way for improved development of drugs that are designed to target gamma-secretase enzymatic activity in Alzheimer's disease and potentially in other neurological diseases. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
PMID: 20129170 [PubMed - indexed for MEDLINE]
- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model J Neurochem. 2011 Sep; 118(5): 928-38 Authors: Fabbro S, Schaller K, Seeds NW Abstract...
- Alzheimer's: Impaired Beta-amyloid Clearance
From the NIH: Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease 09 December 2010 In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers...
- Upcoming Event:alzheimer's Drug Discovery (jersey City, Nj, 14-15 September)
The 10th international conference on Alzheimer's disease drug discovery takes place next week on the 14th and 15th in Jersey City, NJ. From the conference website: "The 10th International Conference on Alzheimer's Disease Drug Discovery is presented...
- Neuropsychology Abstract Of The Day: Sorl1 And Alzheimer Disease
Ekaterina Rogaeva, Yan Meng, Joseph H Lee, Yongjun Gu, Toshitaka Kawarai, et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nature Genetics, Published online: 14 January 2007; | doi:10.1038/ng1943....
- Alzheimer Disease
From The Boston Globe: Mind mystery Alzheimer's disease appears to have multiple causes, and scientists are slowly unraveling them By Alice Dembner, Globe Staff March 29, 2005 A century after Alois Alzheimer identified the debilitating dementia that...